samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > amyloid - those deadly fibrils
PUBLICATIONS
European Biopharmaceutical Review

Amyloid - Those Deadly Fibrils

<p align="justify" class="feature">The term 'amyloid' was introduced in scientific literature in the mid-19th Century to describe macroscopic abnormalities in organs and tissues of patients afflicted with a variety of clinical syndromes. It took almost a century to realise that these amyloid deposits consisted of fibrillar ultrastructures when examined by electron microscopy (see Figure 1).
Subsequently, numerous studies followed which confirmed that deposits of diverse origin show a similar, fibrillar submicroscopic structure consisting of bundles of straight and rigid fibrils. Several amyloid disorders have since been discovered. Although diverse in etiology and pathogenesis, they all demonstrate this accumulation of large fibrillary protein aggregates which interfere with specificorgan functions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Francine Gervais, Vice-President of Research & Development at Neurochem Inc.

As Vice-President of Research and Development, Dr Francine Gervais oversees Neurochem's R&D programme, bringing compounds from discovery through to drug development. Francine came to Neurochem with 15 years' experience in amyloid-related research as an Associate Professor at McGill University. She has been involved in determining the mechanisms responsible for the resistance or susceptibility to disease, including amyloidosis, bacterial and viral infections. Over the years, she has interacted with internationally-renowned research groups on the study of the genetic control of the host response to inflammatory and infectious diseases. Francine holds a PhD in Microbiology and Immunology from the University of Montréal. She began her career with Neurochem as a Consultant, and then joined the company on a full-time basis in June 1997.

spacer
Dr Francine Gervais
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline

Sanofi announced today an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of $90 million for three years plus additional research milestone-based payments.
More info >>

White Papers

Pharmaceutical Companies: Outsourcing Combination Product Manufacturing

Phillips-Medisize

Combination products are therapeutics that combine two or more products (drug/device, biologics/device, biologics/drugs, or drug/device/biologics), regulated and sold as a single unit. Examples of combination products include drug-coated implantable devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement